Cancer prevention agent development program: early phase clinical research

Ended Indefinite Delivery Contract Awarded Last action

Contract number
HHSN261201200042I
Awardee
Awarding agency
Task orders
15 $12,536,064 obligated

Award facts

Opportunity
  • N01CN0501469 Solicitation number
Combined order value
  • $12,536,064 Current, with exercised options
  • $12,617,597 Potential, with all options
Last date to order 100% complete
IDV ceiling 15% used
$85,000,000.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 8 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)

Award details come from SAM.gov/FPDS.

Task orders

Task order Ordering agency Obligated Awarded
Core infrastructure support for the cancer prevention agent development program 75N91019F00129 National Cancer Institute (NIH) $1,793,402
Phase i double- blind, placebo-controlled trial of 0.3MG linaclotide delayed-release (DR1) to demonstrate colorectal… HHSN26100014 National Cancer Institute (NIH) $364,672
A pilot study of MUC1 vaccine in current and former smokers at high risk for lung cancer HHSN26100013 National Cancer Institute (NIH) $785,458
Phase II trial of weekly erlotinib dosing to reduce duadenal polyp burden associated with familial adenomatous polyposis HHSN26100012 National Cancer Institute (NIH) $772,416
Randomized, double-blind, placebo-controlled trial of MUC1 vaccine in patients with newly diagnosed advanced adenoma HHSN26100011 National Cancer Institute (NIH) $89,746
Randomized, double-blind, placebo-controlled trial of meriva (r) as a candidate chemoprevention agent for gastric… HHSN26100010 National Cancer Institute (NIH) $748,354
Core infrastructure support HHSN26100009 National Cancer Institute (NIH) $3,665,425
Core infrastructure support HHSN26100008 National Cancer Institute (NIH) $806,712
Phase i/II trial of a therapeutic DNA vaccine for chronic hepatitis c virus (HCV) infection HHSN26100006 National Cancer Institute (NIH) $725,839
Pilot study of egfr inhibition with erlotinib in cirrhosis to inhibit fibrogenesis and prevent hepatocellular carcinoma HHSN26100007 National Cancer Institute (NIH) $536,992
R & d- dose DE-escalation trial to identify the lowest commercially available dose of linaclotide that maintains… HHSN26100005 National Cancer Institute (NIH) $165,774
Core infrastructure support HHSN26100004 National Cancer Institute (NIH) $658,179
MUC1 vaccine in patients with newly diagnosed advanced adenomas HHSN26100003 National Cancer Institute (NIH) $915,331
Core infrastructure support HHSN26100001 National Cancer Institute (NIH) $259,490
Phase 0 trial of linaclotide to demonstrate colorectal bioactivity in healthy volunteers HHSN26100002 National Cancer Institute (NIH) $248,273
Show all 15

Transactions

Action Obligated Date
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Exercise an Option 4 $0
Exercise an Option 3 $0
Other Administrative Action 2 $0
Change Order 1 $0
Original award $0

Quick answers

Who was awarded contract HHSN261201200042I?

HHSN261201200042I was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on September 24, 2012.

How much is contract HHSN261201200042I worth?

Orders under HHSN261201200042I have obligated $12,536,064. Their combined potential value, with all options, is $12,617,597. HHSN261201200042I's own ceiling is $85,000,000.

How many orders have been placed under contract HHSN261201200042I?

15 orders have been placed under HHSN261201200042I, the latest on September 23, 2019.

Who can order from contract HHSN261201200042I?

HHSN261201200042I is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract HHSN261201200042I competed?

The extent of competition for HHSN261201200042I was full and open competition. The government received 8 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login